Literature DB >> 12623219

Activation of 5-HT(1A) autoreceptors enhances the inhibitory effect of galanin on hippocampal 5-HT release in vivo.

T Yoshitake1, S Yoshitake, M Yamaguchi, S O Ogren, J Kehr.   

Abstract

The microdialysis technique was used to examine interactions between 5-HT(1A) and galanin receptors in the dorsal raphe nucleus (DRN), by measuring the extracellular levels of 5-HT in the ventral hippocampus of awake rats. The rats were pretreated with the 5-HT(1A) receptor agonist (R,S)-8-OH-DPAT (0.3 mg/kg, s.c.) or saline. 8-OH-DPAT caused a time-dependent reduction of basal 5-HT levels down to 43-48% at 40 min while at 140 min, the hippocampal 5-HT had returned to control values. At that time point, the rats received a second injection of 8-OH-DPAT or galanin (0.15, 0.5 and 1.5 nmol/0.5 microl) infused into the lateral ventricle. The second injection of 8-OH-DPAT caused a significantly smaller reduction of hippocampal 5-HT levels. In contrast, galanin at all three doses in the 8-OH-DPAT-pretreated groups, was significantly more potent in reducing 5-HT levels (maximal reduction to 74%, 52% and 49%, respectively) than it was in saline-pretreated rats (maximal reduction to 96%, 85% and 69%, respectively). The inhibitory effect of galanin (1.5 nmol) on extracellular 5-HT levels in the rat hippocampus was significantly attenuated by co-administration of the 5-HT(1A) receptor antagonists WAY-100635 (0.3 and 0.6 mg/kg s.c.) and, to a lesser extent, with pindolol (20 mg/kg s.c.). These data provide direct in vivo evidence of agonistic 5-HT(1A)-galanin receptor interaction at the presynaptic level. Furthermore, the findings indicate that a down-regulation of the somato-dendritic 5-HT(1A) autoreceptors, following their stimulation with 8-OH-DPAT and possibly also indirectly with 5-HT reuptake inhibitors, may be compensated by a subsequent 'sensitization' of the inhibitory galanin receptors in the DRN. Thus, the enhanced galanin receptor-mediated inhibition of 5-HT neurotransmission may contribute to the pathophysiology of depression or to the reduced and delayed efficacy of antidepressant therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623219     DOI: 10.1016/s0028-3908(02)00373-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

Review 1.  Galanin and its receptors in neurological disorders.

Authors:  Linda Lundström; Anna Elmquist; Tamas Bartfai; Ulo Langel
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 2.  Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.

Authors:  Sven Ove Ogren; Eugenia Kuteeva; Tomas Hökfelt; Jan Kehr
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Relationship between climacteric symptoms and serum galanin levels in post-menopausal women.

Authors:  R Słopien; B Meczekalski; A Warenik-Szymankiewicz
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

4.  A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus.

Authors:  Xiaoying Lu; Alasdair M Barr; Jefferson W Kinney; Pietro Sanna; Bruno Conti; M Margarita Behrens; Tamas Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

5.  Trace amine-associated receptor 1 as a monoaminergic modulator in brain.

Authors:  Zhihua Xie; Gregory M Miller
Journal:  Biochem Pharmacol       Date:  2009-05-29       Impact factor: 5.858

Review 6.  Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.

Authors:  Konstantinos A Paschos; Stavroula Veletza; Ekaterini Chatzaki
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.